Key result
LPL-positive patients had a significantly shorter median treatment-free survival time compared to LPL-negative patients (23 vs 88 months; P=0.002).
Why the study?
Does LPL mRNA expression predict prognosis and IGHV mutation status in patients with B Cell Chronic Lymphocytic Leukemia?
Population
50 patients with B Cell Chronic Lymphocytic Leukemia (CLL)
Design
Cohort
Authors
Loading...
LPL mRNA expression measured via qPCR in whole blood is a valuable prognostic marker in CLL that correlates with IGHV mutation status and survival.
Observational (n=50)
Does LPL mRNA expression predict prognosis and IGHV mutation status in patients with B Cell Chronic Lymphocytic Leukemia?
Absolute Event Rate: 23% vs 88%
p-value: p=0.002
LPL mRNA expression measured via qPCR in whole blood is a valuable prognostic marker in CLL that correlates with IGHV mutation status and survival.
Bockstaele et al. (2006) conducted an observational in Chronic lymphocytic leukemia (CLL) (n=50). LPL mRNA expression (LPL-positive) vs. LPL-negative was evaluated on Median treatment-free survival (months) (p=0.002). LPL-positive patients had a significantly shorter median treatment-free survival time compared to LPL-negative patients (23 vs 88 months; P=0.002).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: